S&P 500   3,571.37 (+0.39%)
DOW   29,452.76 (+0.65%)
QQQ   289.76 (-0.21%)
AAPL   115.23 (-1.80%)
MSFT   209.39 (-0.48%)
FB   265.33 (-1.62%)
GOOGL   1,724.67 (-0.67%)
AMZN   3,096.12 (-0.11%)
TSLA   519.00 (+6.00%)
NVDA   524.00 (+0.09%)
BABA   267.00 (-1.38%)
CGC   23.74 (+0.08%)
GE   10.16 (+4.10%)
MU   63.66 (+3.68%)
AMD   86.31 (+1.97%)
T   28.51 (+0.67%)
NIO   51.35 (+4.26%)
F   8.95 (+2.40%)
ACB   6.98 (-2.10%)
GILD   59.91 (-0.33%)
NFLX   483.00 (-1.07%)
BA   205.64 (+3.02%)
DIS   142.36 (+0.91%)
S&P 500   3,571.37 (+0.39%)
DOW   29,452.76 (+0.65%)
QQQ   289.76 (-0.21%)
AAPL   115.23 (-1.80%)
MSFT   209.39 (-0.48%)
FB   265.33 (-1.62%)
GOOGL   1,724.67 (-0.67%)
AMZN   3,096.12 (-0.11%)
TSLA   519.00 (+6.00%)
NVDA   524.00 (+0.09%)
BABA   267.00 (-1.38%)
CGC   23.74 (+0.08%)
GE   10.16 (+4.10%)
MU   63.66 (+3.68%)
AMD   86.31 (+1.97%)
T   28.51 (+0.67%)
NIO   51.35 (+4.26%)
F   8.95 (+2.40%)
ACB   6.98 (-2.10%)
GILD   59.91 (-0.33%)
NFLX   483.00 (-1.07%)
BA   205.64 (+3.02%)
DIS   142.36 (+0.91%)
S&P 500   3,571.37 (+0.39%)
DOW   29,452.76 (+0.65%)
QQQ   289.76 (-0.21%)
AAPL   115.23 (-1.80%)
MSFT   209.39 (-0.48%)
FB   265.33 (-1.62%)
GOOGL   1,724.67 (-0.67%)
AMZN   3,096.12 (-0.11%)
TSLA   519.00 (+6.00%)
NVDA   524.00 (+0.09%)
BABA   267.00 (-1.38%)
CGC   23.74 (+0.08%)
GE   10.16 (+4.10%)
MU   63.66 (+3.68%)
AMD   86.31 (+1.97%)
T   28.51 (+0.67%)
NIO   51.35 (+4.26%)
F   8.95 (+2.40%)
ACB   6.98 (-2.10%)
GILD   59.91 (-0.33%)
NFLX   483.00 (-1.07%)
BA   205.64 (+3.02%)
DIS   142.36 (+0.91%)
S&P 500   3,571.37 (+0.39%)
DOW   29,452.76 (+0.65%)
QQQ   289.76 (-0.21%)
AAPL   115.23 (-1.80%)
MSFT   209.39 (-0.48%)
FB   265.33 (-1.62%)
GOOGL   1,724.67 (-0.67%)
AMZN   3,096.12 (-0.11%)
TSLA   519.00 (+6.00%)
NVDA   524.00 (+0.09%)
BABA   267.00 (-1.38%)
CGC   23.74 (+0.08%)
GE   10.16 (+4.10%)
MU   63.66 (+3.68%)
AMD   86.31 (+1.97%)
T   28.51 (+0.67%)
NIO   51.35 (+4.26%)
F   8.95 (+2.40%)
ACB   6.98 (-2.10%)
GILD   59.91 (-0.33%)
NFLX   483.00 (-1.07%)
BA   205.64 (+3.02%)
DIS   142.36 (+0.91%)
Log in
NASDAQ:APVO

Aptevo Therapeutics Stock Forecast, Price & News

$42.62
-3.01 (-6.60 %)
(As of 11/23/2020 10:28 AM ET)
Add
Compare
Today's Range
$42.62
Now: $42.62▼
$45.10
50-Day Range
$6.21
MA: $16.39▼
$48.36
52-Week Range
$2.94
Now: $42.62▼
$60.00
Volume512 shs
Average Volume708,083 shs
Market Capitalization$176.66 million
P/E RatioN/A
Dividend YieldN/A
Beta2.52
Aptevo Therapeutics Inc., a clinical-stage biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed product includes IXINITY, a coagulation factor IX therapeutic indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations. Its lead clinical candidate is APVO436, a bispecific immunotherapeutic protein that is in Phase 1/1b clinical trial for acute myeloid leukemia and high-grade myelodysplastic syndrome. The company's preclinical candidates include ALG.APV-527, a bispecific antibody to target 4-1BB x 5T4; APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40; and other pre-clinical development stage therapeutics focused on immuno-oncology. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Read More
Aptevo Therapeutics logo

Beat the Market (BTM) Rank™

Analyst Opinion: 1.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

1.24 out of 5 stars


Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:APVO
Previous Symbol
CUSIPN/A
CIK1671584
Webwww.aptevotherapeutics.com
Phone206-838-0500
Employees80

Debt

Debt-to-Equity Ratio11.44
Current Ratio4.13
Quick Ratio4.13

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$32.42 million
Price / Sales5.45
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.53 per share
Price / Book80.42

Profitability

EPS (Most Recent Fiscal Year)($15.27)
Net Income$-40,450,000.00
Net MarginsN/A
Return on Equity-345.40%
Return on Assets-97.13%

Miscellaneous

Outstanding Shares4,145,000
Market Cap$176.66 million
Next Earnings Date3/24/2021 (Estimated)
OptionableOptionable
$42.62
-3.01 (-6.60 %)
(As of 11/23/2020 10:28 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive APVO News and Ratings via Email

Sign-up to receive the latest news and ratings for APVO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Aptevo Therapeutics (NASDAQ:APVO) Frequently Asked Questions

How has Aptevo Therapeutics' stock price been impacted by the U.S. election?

Aptevo Therapeutics' stock was trading at $6.30 on November 3rd, 2020 when the U.S. election occured and Joe Biden was elected president. Since then, APVO shares have increased by 624.3% and is now trading at $45.63.
View which stocks have been most impacted by the election.

How has Aptevo Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Aptevo Therapeutics' stock was trading at $0.42 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, APVO shares have increased by 10,764.3% and is now trading at $45.63.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of Aptevo Therapeutics?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aptevo Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Aptevo Therapeutics.

What stocks does MarketBeat like better than Aptevo Therapeutics?

Wall Street analysts have given Aptevo Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Aptevo Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Aptevo Therapeutics' next earnings date?

Aptevo Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, March 24th 2021.
View our earnings forecast for Aptevo Therapeutics.

How were Aptevo Therapeutics' earnings last quarter?

Aptevo Therapeutics Inc. (NASDAQ:APVO) announced its quarterly earnings results on Sunday, November, 15th. The biotechnology company reported ($2.15) EPS for the quarter, missing the consensus estimate of ($2.05) by $0.10.
View Aptevo Therapeutics' earnings history.

What price target have analysts set for APVO?

2 Wall Street analysts have issued twelve-month price objectives for Aptevo Therapeutics' stock. Their forecasts range from $32.00 to $32.00. On average, they expect Aptevo Therapeutics' stock price to reach $32.00 in the next twelve months. This suggests that the stock has a possible downside of 29.9%.
View analysts' price targets for Aptevo Therapeutics.

Are investors shorting Aptevo Therapeutics?

Aptevo Therapeutics saw a decline in short interest during the month of October. As of October 15th, there was short interest totaling 84,900 shares, a decline of 15.1% from the September 30th total of 100,000 shares. Based on an average daily trading volume, of 53,000 shares, the days-to-cover ratio is presently 1.6 days. Currently, 3.0% of the shares of the company are short sold.
View Aptevo Therapeutics' Short Interest.

Who are some of Aptevo Therapeutics' key competitors?

Some companies that are related to Aptevo Therapeutics include Zafgen (ZFGN), Radius Health (RDUS), Kadmon (KDMN), Kadmon (KDMN), AnaptysBio (ANAB), Omeros (OMER), Gossamer Bio (GOSS), Vanda Pharmaceuticals (VNDA), Five Prime Therapeutics (FPRX), MannKind (MNKD), Albireo Pharma (ALBO), DiaMedica Therapeutics (DMCAF), VBI Vaccines (VBIV), Emisphere Technologies (EMIS) and Akouos (AKUS).
View all competitors.

What other stocks do shareholders of Aptevo Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aptevo Therapeutics investors own include Advanced Micro Devices (AMD), Amarin (AMRN), AVEO Pharmaceuticals (AVEO), Alibaba Group (BABA), Micron Technology (MU), OPKO Health (OPK), AbbVie (ABBV), Aurinia Pharmaceuticals (AUPH), BioXcel Therapeutics (BTAI) and T2 Biosystems (TTOO).

Who are Aptevo Therapeutics' key executives?

Aptevo Therapeutics' management team includes the following people:
  • Mr. Marvin L. White, Pres, CEO & Director (Age 58, Pay $779.77k)
  • Mr. Jeffrey G. Lamothe, Sr. VP, CFO & Treasurer (Age 54, Pay $533.81k)
  • Dr. Jane A. Gross, Sr. VP & Chief Scientific Officer (Age 63, Pay $485.68k)
  • Mr. Randy Joe Maddux, Sr. VP of Operations & Chief Manufacturing Officer (Age 59)
  • Ms. Stacey Jurchison, Sr. Director of Investor Relations & Corp. Communications

What is Aptevo Therapeutics' stock symbol?

Aptevo Therapeutics trades on the NASDAQ under the ticker symbol "APVO."

Who are Aptevo Therapeutics' major shareholders?

Aptevo Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Acadian Asset Management LLC (1.40%), GSA Capital Partners LLP (1.25%) and Worth Venture Partners LLC (0.67%). Company insiders that own Aptevo Therapeutics stock include Barbara Lopez Kunz, Daniel Abdun-Nabi, Fuad El-Hibri, Grady Grant III, Kevin C Tang, Marvin L White, Randy Joe Maddux and Zsolt Harsanyi.
View institutional ownership trends for Aptevo Therapeutics.

Which institutional investors are selling Aptevo Therapeutics stock?

APVO stock was sold by a variety of institutional investors in the last quarter, including Worth Venture Partners LLC, and Acadian Asset Management LLC.
View insider buying and selling activity for Aptevo Therapeutics.

Which institutional investors are buying Aptevo Therapeutics stock?

APVO stock was bought by a variety of institutional investors in the last quarter, including GSA Capital Partners LLP. Company insiders that have bought Aptevo Therapeutics stock in the last two years include Barbara Lopez Kunz, Daniel Abdun-Nabi, Fuad El-Hibri, Grady Grant III, Kevin C Tang, Marvin L White, Randy Joe Maddux, and Zsolt Harsanyi.
View insider buying and selling activity for Aptevo Therapeutics.

How do I buy shares of Aptevo Therapeutics?

Shares of APVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Aptevo Therapeutics' stock price today?

One share of APVO stock can currently be purchased for approximately $45.63.

How big of a company is Aptevo Therapeutics?

Aptevo Therapeutics has a market capitalization of $189.14 million and generates $32.42 million in revenue each year. The biotechnology company earns $-40,450,000.00 in net income (profit) each year or ($15.27) on an earnings per share basis. Aptevo Therapeutics employs 80 workers across the globe.

What is Aptevo Therapeutics' official website?

The official website for Aptevo Therapeutics is www.aptevotherapeutics.com.

How can I contact Aptevo Therapeutics?

Aptevo Therapeutics' mailing address is 2401 4TH AVENUE SUITE 1050, SEATTLE WA, 98121. The biotechnology company can be reached via phone at 206-838-0500 or via email at [email protected]

This page was last updated on 11/23/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.